Ola CEO Bhavish Aggarwal teased an image of the battery pack for the company's upcoming electric motorcycle models: Diamondhead, Adventure,...

Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...

Are you looking for the best ring lights in India for home? If so, then continue reading our article where we have shared a list of the bes...

The operating margin of 27% has been above the company's long term guidance of 25%. However, the good performance was dented after the comp...

DRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and str...

After peaking in 2015, Indian pharma stocks are back in favour due to improved fundamentals of the companies.

DRL’s strategy pivot, with focus on the core areas of US generics, India and emerging markets, has been yielding results.

The sector has its own battles to fight – which are more regulatory, global and endemic in nature.

With the launch date of the next-gen Fortuner declared as November 7, 2016, the Japanese automaker has given a 'register' tab on its websit...

Seven pharma cos' managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook's healthy.

The stock of Dr Reddy's Labs declined 8.2% on Thursday on the company receiving a stern warning letter from the US FDA concerning its three...

The Sensex finally closed 151.84 points higher or 0.57 per cent at 27,019.39. It hit a record high of 27082.85 and a low of 26886.22 in tra...

Even as environmentalists have been crying foul over the severe pollution of water bodies in the city, including Hussainsagar lake, the aut...

The Hyderabad-based company with FY12 net sales Rs 9674 crore is expected to report good results to the cheer of its investors.

Dr Reddy's Laboratories (DRL) has split a key marketing division into two parts in a bid to resurrect its ailing domestic business.

Dr Reddys Labs' fourth quarter results were better than expected. The market responded positively to this with the stock closing higher at ...

A good show in the third quarter aside, a district court ruling in the US has now come as a shot in the arm for Dr Reddy's Labs, or DRL.